Nimesh S A Patel

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi Urocortin does not reduce the renal injury and dysfunction caused by experimental ischaemia/reperfusion
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, UK
    Eur J Pharmacol 496:175-80. 2004
  2. pmc Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock
    Kiran K Nandra
    William Harvey Research Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    Dis Model Mech 6:701-9. 2013
  3. pmc Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury
    Nimesh S A Patel
    Queen Mary University of London, Barts and the London School of Medicine and Dentistry, The William Harvey Research Institute, London, UK
    Mol Med 18:719-27. 2012
  4. pmc A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock
    Nimesh S A Patel
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, William Harvey Research Institute, Barts and The London, London, UK
    Mol Med 17:883-92. 2011
  5. pmc Erythropoietin in the intensive care unit: beyond treatment of anemia
    Nimesh Sa Patel
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, William Harvey Research Institute, Barts and The London, London, UK
    Ann Intensive Care 1:40. 2011
  6. ncbi The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo
    Nimesh S A Patel
    Centre for Experimental Medicine and Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Eur J Pharmacol 562:148-54. 2007
  7. doi Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury
    Nimesh S A Patel
    Centre for Translational Medicine and Nephrology, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom
    J Pharmacol Exp Ther 328:635-43. 2009
  8. ncbi Inhibiting glycogen synthase kinase 3beta in sepsis
    Laura Dugo
    Centre for Experimental Medicine, Nephrology and Critical Care Medicine, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London ECIM 6BQ, UK
    Novartis Found Symp 280:128-42; discussion 142-6, 160-4. 2007
  9. ncbi Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock
    Maha Abdelrahman
    Centre of Experimental Medicine, Nephrology, and Critical Care, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, London EC1M 6BQ, UK
    Shock 23:107-14. 2005
  10. ncbi GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury
    Prabal K Chatterjee
    Department of Experimental Medicine and Nephrology, The William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London, United Kingdom
    Kidney Int 63:853-65. 2003

Collaborators

Detail Information

Publications52

  1. ncbi Urocortin does not reduce the renal injury and dysfunction caused by experimental ischaemia/reperfusion
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, UK
    Eur J Pharmacol 496:175-80. 2004
    ..Thus, we propose that the pharmacological application of urocortin does not reduce the renal injury caused by bilateral renal ischaemia/reperfusion...
  2. pmc Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock
    Kiran K Nandra
    William Harvey Research Institute, Barts and London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    Dis Model Mech 6:701-9. 2013
    ....
  3. pmc Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury
    Nimesh S A Patel
    Queen Mary University of London, Barts and the London School of Medicine and Dentistry, The William Harvey Research Institute, London, UK
    Mol Med 18:719-27. 2012
    ..Interestingly, the phosphorylation of endothelial nitric oxide synthase was enhanced by EPO and, to a much lesser extent, by pHBSP, suggesting that the signaling pathways activated by EPO and pHBSP may not be identical...
  4. pmc A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock
    Nimesh S A Patel
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, William Harvey Research Institute, Barts and The London, London, UK
    Mol Med 17:883-92. 2011
    ....
  5. pmc Erythropoietin in the intensive care unit: beyond treatment of anemia
    Nimesh Sa Patel
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, William Harvey Research Institute, Barts and The London, London, UK
    Ann Intensive Care 1:40. 2011
    ..This review article summarizes what is known in preclinical models of critical illness and discusses why this does not correlate with randomized, controlled clinical trials...
  6. ncbi The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo
    Nimesh S A Patel
    Centre for Experimental Medicine and Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Eur J Pharmacol 562:148-54. 2007
    ....
  7. doi Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury
    Nimesh S A Patel
    Centre for Translational Medicine and Nephrology, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom
    J Pharmacol Exp Ther 328:635-43. 2009
    ....
  8. ncbi Inhibiting glycogen synthase kinase 3beta in sepsis
    Laura Dugo
    Centre for Experimental Medicine, Nephrology and Critical Care Medicine, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London ECIM 6BQ, UK
    Novartis Found Symp 280:128-42; discussion 142-6, 160-4. 2007
    ..We propose that GSK-3beta inhibition may be useful in the therapy of sepsis, shock and other diseases associated with local or systemic inflammation...
  9. ncbi Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock
    Maha Abdelrahman
    Centre of Experimental Medicine, Nephrology, and Critical Care, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, London EC1M 6BQ, UK
    Shock 23:107-14. 2005
    ....
  10. ncbi GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury
    Prabal K Chatterjee
    Department of Experimental Medicine and Nephrology, The William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London, United Kingdom
    Kidney Int 63:853-65. 2003
    ..The aim of this study was to investigate the effects of GW274150, a novel, highly selective, potent and long-acting inhibitor of iNOS activity in rat and mouse models of renal I/R...
  11. ncbi GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat
    Laura Dugo
    Centre for Experimental Medicine, Nephrology and Critical Care Medicine, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK
    Crit Care Med 33:1903-12. 2005
    ..Here we investigate the effects of GSK-3beta inhibition on organ injury/dysfunction caused by lipopolysaccharide or coadministration of lipopolysaccharide and peptidoglycan in the rat...
  12. ncbi The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure
    Prabal Kumar Chatterjee
    Department of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    Cardiovasc Res 61:630-43. 2004
    ..Here we investigate the effects of the endogenous prostaglandin D2 metabolite 15-deoxy-Delta(12,14)-prostaglandin J2, on the renal dysfunction and injury caused by ischemia/reperfusion of the kidney...
  13. pmc Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse
    Sina M Coldewey
    Queen Mary University of London, Barts and the London School of Medicine and Dentistry, The William Harvey Research Institute, London, EC1M 6BQ, UK
    Dis Model Mech 6:1031-42. 2013
    ..We suggest that this protective effect is (at least in part) attributable to inhibition of inflammation through NF-κB, the subsequent decrease in iNOS expression and the activation of the Akt-eNOS survival pathway. ..
  14. ncbi Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton
    Marika Collin
    Centre for Experimental Medicine, Nephrology and Critical Care, The William Harvey Research Institute, Queen Mary, University of London, UK
    J Leukoc Biol 76:961-70. 2004
    ....
  15. ncbi The tyrosine kinase inhibitor tyrphostin AG126 reduces renal ischemia/reperfusion injury in the rat
    Prabal K Chatterjee
    Department of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
    Kidney Int 64:1605-19. 2003
    ..We investigate the effects of tyrphostin AG126, an inhibitor of tyrosine kinase activity, on the renal dysfunction and injury caused by ischemia/reperfusion (I/R) of the kidney...
  16. ncbi Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London, EC1M 6BQ, UK
    J Am Soc Nephrol 16:712-9. 2005
    ..Thus, it is proposed that endogenous PARG(110) plays a pivotal role in the pathophysiology of I/R injury of the kidney...
  17. ncbi Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology, and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    J Pharmacol Exp Ther 312:1170-8. 2005
    ..We propose that endogenous IL-6 enhances the degree of renal injury, dysfunction, and inflammation caused by I/R of the kidney by promoting the expression of adhesion molecules and subsequent oxidative and nitrosative stress...
  18. ncbi Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, United Kingdom
    Mol Pharmacol 66:220-7. 2004
    ....
  19. ncbi High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury
    Christoph Thiemermann
    Department of Experimental Medicine and Nephrology, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
    J Am Soc Nephrol 14:1833-43. 2003
    ..It is proposed that the mechanism of protection involves reduction of the expression of adhesion molecules, resulting in reduction of PMN infiltration and oxidative stress...
  20. ncbi GW274150 inhibits nitric oxide production by primary cultures of rat proximal tubular cells
    Prabal K Chatterjee
    Department of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, UK
    Med Sci Monit 9:BR357-62. 2003
    ..Here we investigate the effects of GW274150, a potent, long-acting and highly selective inhibitor of iNOS activity, on NO production by primary cultures of rat proximal tubular cells (PTC)...
  21. ncbi EUK-134 reduces renal dysfunction and injury caused by oxidative and nitrosative stress of the kidney
    Prabal K Chatterjee
    Department of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, London, UK
    Am J Nephrol 24:165-77. 2004
    ....
  22. ncbi Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury
    Ahila Sivarajah
    Department of Experimental Medicine and Nephrology, William Harvey Research Institute, Queen Mary University of London, UK
    Am J Nephrol 23:267-76. 2003
    ..Here we investigate the effects of the PPAR-gamma agonists, rosiglitazone and ciglitazone, on the renal dysfunction and injury caused by I/R of the rat kidney in vivo...
  23. ncbi Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo
    Nimesh S A Patel
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
    Kidney Int 66:983-9. 2004
    ..Here we investigate the effects of renal ischemia/reperfusion (I/R) on the degree of renal dysfunction and injury with recombinant human EPO in mice when given as either a 3-day pretreatment, or upon reperfusion of the kidney...
  24. pmc Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor
    Areeg I Khan
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, The William Harvey Research Institute, EC1M 6BQ, London, UK
    Dis Model Mech 6:1021-30. 2013
    ..Erythropoietin attenuates the impaired systolic contractility associated with sepsis by activation of the β-common receptor, which, in turn, results in activation of survival pathways and inhibition of inflammation. ..
  25. ncbi TEMPONE reduces renal dysfunction and injury mediated by oxidative stress of the rat kidney
    Nimesh S A Patel
    Department of Experimental Medicine and Nephrology, The William Harvey Research Institute, London, England
    Free Radic Biol Med 33:1575-89. 2002
    ....
  26. ncbi Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase
    Pinpat Tripatara
    Centre for Experimental Medicine and Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
    J Am Soc Nephrol 18:570-80. 2007
    ..These observations suggest that nitrite therapy might prove beneficial in protecting kidney function and integrity during periods of I/R such as those encountered in renal transplantation...
  27. doi Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat
    Kiran K Nandra
    The William Harvey Research Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Shock 37:592-8. 2012
    ....
  28. pmc Dexamethasone ameliorates renal ischemia-reperfusion injury
    Sanjeev Kumar
    Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, St Bartholomew s, University of London, London EC1M 6BQ, United Kingdom
    J Am Soc Nephrol 20:2412-25. 2009
    ..In summary, in the setting of renal ischemia-reperfusion injury, dexamethasone directly protects against kidney injury by a receptor-dependent, nongenomic mechanism...
  29. doi Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction
    Pinpat Tripatara
    Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Lab Invest 88:1038-48. 2008
    ....
  30. ncbi Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin
    Marika Collin
    William Harvey Research Institute, Department of Experimental Medicine, Nephrology and Critical Care, St Bartholomew s, and the Royal London School of Medicine and Dentistry, London, UK
    Crit Care Med 32:826-31. 2004
    ..Here we investigate the effects of 15 d-PGJ2 on the multiple organ injury/dysfunction associated with severe endotoxemia...
  31. ncbi The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion
    Massimo Collino
    Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Kidney Int 68:529-36. 2005
    ..Here we investigate the hypothesis that the renoprotective effects of LPS may be due to an enhanced formation of endogenous ligands of PPARgamma, rather than an up-regulation of PPARgamma expression...
  32. doi Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock
    Amar Kapoor
    Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, London, United Kingdom
    Am J Respir Crit Care Med 182:1506-15. 2010
    ..Peroxisome proliferator-activated receptor (PPAR)-β/δ is a transcription factor that belongs to the PPAR nuclear hormone receptor family, but the role of PPAR-β/δ in sepsis is unknown...
  33. doi Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study
    Pinpat Tripatara
    Centre for Translational Medicine and Therapeutics, Queen Mary University of London, The William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, London, UK
    Eur J Pharmacol 606:205-9. 2009
    ....
  34. doi Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor
    Sina M Coldewey
    The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
    Kidney Int 84:482-90. 2013
    ..Thus, activation of the βcR by EPO is essential for the observed reduction in AKI in either endotoxemic young mice or older mice with polymicrobial sepsis, and for the activation of well-known signaling pathways by EPO. ..
  35. ncbi Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia
    Maha Abdelrahman
    Centre of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, St Bartholomew s and the Royal London School of Medicine and Dentistry, London EC1M 6BQ, United Kingdom
    Shock 22:63-9. 2004
    ..We propose that the acute administration of EPO on reperfusion and/or resuscitation will reduce the tissue injury caused by ischemia-reperfusion of the heart (and other organs) and hemorrhagic shock...
  36. ncbi Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury
    Prabal K Chatterjee
    Department of Experimental Medicine and Nephrology, The William Harvey Research Institute, St Bartholomew s, Charterhouse Square, London, EC1M 6BQ England, United Kingdom
    Kidney Int 61:862-71. 2002
    ....
  37. pmc Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury
    Christoph Scheiermann
    Barts and the London School of Medicine and Dentistry, Queen Mary University of London, William Harvey Research Institute, London, UK
    Arterioscler Thromb Vasc Biol 29:1509-15. 2009
    ..Here we investigated the role of JAM-C in leukocyte migration in response to ischemia reperfusion (I/R) injury...
  38. pmc Gender dimorphism of the cardiac dysfunction in murine sepsis: signalling mechanisms and age-dependency
    Jianmin Chen
    Queen Mary University of London, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    PLoS ONE 9:e100631. 2014
    ..It should be noted that the observed gender dimorphism of the cardiac dysfunction in sepsis was not seen when a very severe stimulus (high dose of LPS/PepG co-administration) was used to cause cardiac dysfunction. ..
  39. ncbi Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice
    Salvatore Cuzzocrea
    Institute of Pharmacology, School of Medicine, Torre Biologicala, Policlinico Universitario, University of Messina, Via C Valeria Gazzi, 98100, Messina, Italy
    Intensive Care Med 29:2016-25. 2003
    ..Dithiocarbamates are anti-oxidants which are potent inhibitors of NF-kappaB. We postulated that pyrrolidine dithiocarbamate (PDTC) would attenuate multiple-organ failure (MOF)...
  40. ncbi Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma
    Salvatore Cuzzocrea
    University of Messina, Messina, Italy
    Arthritis Rheum 48:3544-56. 2003
    ..The aim of this study was to investigate the effects of rosiglitazone on the inflammatory response in mice with collagen-induced arthritis (CIA)...
  41. ncbi Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Torre Biologica, Policlinico Universitario Via C Valeria, Gazzi, 98100 Messina, Italy
    Eur J Pharmacol 483:79-93. 2004
    ..We propose that rosiglitazone and other potent PPAR-gamma agonists may be useful in the therapy of inflammation...
  42. ncbi High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, 98100 Messina, Italy
    Shock 21:342-51. 2004
    ..Thus, recHDL reduces the inflammation caused by intestinal I/R and colitis. HDLs may represent a novel therapeutic approach for the therapy of inflammation of the gut...
  43. pmc Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, Torre Biologica, Policlinico Universitario, 98123 Messina, Italy
    Br J Pharmacol 140:366-76. 2003
    ..8. These results demonstrate that the two PPAR-gamma agonists, rosiglitazone and 15d-PGJ2, significantly reduce I/R injury of the intestine...
  44. ncbi Erythropoietin reduces the development of experimental inflammatory bowel disease
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Torre Biologica, Policino Universitario, Italy
    J Pharmacol Exp Ther 311:1272-80. 2004
    ..Thus, treatment of rat with EPO reduces the degree of colitis caused by DNBS. We propose that EPO may be useful in the treatment of inflammatory bowel disease...
  45. ncbi Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma
    Tiziana Genovese
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Torre Biologica, Policlinico Universitario Via C Valeria, Gazzi, 98100 Messina, Italy
    J Pharmacol Exp Ther 312:449-57. 2005
    ..Taken together, our results clearly demonstrate that treatment with PARP inhibitors reduces the development of inflammation and tissue injury events associated with spinal cord trauma...
  46. pmc Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice
    Virginie Petrilli
    International Agency for Research on Cancer, 69008 Lyons, France
    J Clin Invest 114:1072-81. 2004
    ..This study provides a novel insight into the function of PARP-1 in inflammation and ischemia-related pathophysiologies...
  47. pmc Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
    Michael Brines
    Warren Pharmaceuticals, Ossining, NY 10562, USA
    Proc Natl Acad Sci U S A 105:10925-30. 2008
    ..Thus, the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure...
  48. ncbi Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, Policlinico Universitario, Messina, Italy
    Crit Care Med 32:457-66. 2004
    ..In the present study, we investigated the effects of rosiglitazone on the development of nonseptic shock caused by zymosan in mice...
  49. ncbi Tempol reduces the activation of nuclear factor-kappaB in acute inflammation
    Salvatore Cuzzocrea
    Department of Clinical and Experimental Medicine and Pharmacology, Torre Biologica, Policlinico Universitario, 98123 Messina, Italy
    Free Radic Res 38:813-9. 2004
    ..These data confirm that Tempol exerts potent anti-inflammatory properties and clearly demonstrates for the first time that Tempol reduces the activation of NF-kappaB in vivo...
  50. ncbi Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse
    Salvatore Cuzzocrea
    University of Messina, Messina, Italy
    Arthritis Rheum 52:940-50. 2005
    ..Erythropoietin (EPO) is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. The aim of this study was to investigate the effect of EPO on collagen-induced arthritis (CIA) in the mouse...
  51. ncbi Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid
    Rosanna Di Paola
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina Torre Biologica, Policlinico Universitario, 98123 Messina, Italy
    Eur J Pharmacol 507:281-9. 2005
    ..Thus, GW274150 treatment reduced the degree of colitis caused by dinitrobenzene sulfonic acid. We propose that selective inhibition of iNOS activity with GW274150 may be useful in the treatment of inflammatory bowel disease...